US panel OK with prostate-cancer tests, with caveats
CHICAGO — An influential U.S. government advisory panel is dropping its opposition to routine prostatecancer screening in favor of letting men decide for themselves after talking with their doctor.
The new draft guidelines released Tuesday echo those of several leading medical groups, but they don’t make the decision any easier for men: With their doctor’s help, they have to decide whether to take an imperfect PSA test that has a small chance of detecting a deadly cancer and a larger chance of triggering unneeded worry and treatment with serious side effects.
“This isn’t a one-size-fits-all” recommendation, said the panel’s chair, Dr. Kirsten BibbinsDomingo, a San Francisco internist who already follows the advice and discusses the potential pros and cons with her patients.
Men whose greatest concern is reducing their chances of dying from cancer are sometimes willing to face the consequences and choose testing. “Other men will realize the likely benefit is small and aren’t willing to risk the harms,” she said.
PSA screening to detect the most common male cancer is among the most heated topics in men’s health. It involves a simple blood test for elevated levels of a protein that may signal cancer but also can be caused by less-serious prostate problems. It can find cancer that frequently doesn’t need treatment because it’s too small and slow-growing to become deadly. Doctors say there’s no good way to tell which early cancers might become lethal. The next step is often radiation or surgery to remove the prostate, which may result in impotence and incontinence.
The new recommendations come from the U.S. Preventive Services Task Force, a government-appointed volunteer panel of experts. The group says the change is based on new evidence indicating that routine PSA blood tests can slightly reduce some men’s chances of dying from prostate cancer and that drastic treatment can sometimes be avoided with close monitoring when cancer is detected.
The shift shelves the panel’s 2012 guidance, which prompted criticism from some urologists — specialists who treat the disease — and angered some prostate-cancer patients certain that PSA screening had saved their lives.
The new advice published Tuesday closely aligns the panel with medical groups that also support shared decision-making. The biggest remaining difference is timing. The task force draft says screening conversations should begin at age 55. Other groups say start earlier, depending on family history of prostate cancer and other factors. It recommends against testing men aged 70 and older.
The panel leaves open how often men should be screened. It does not recommend earlier testing for blacks and those with a family history but says they should know their risks are higher.